Cargando…

Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients

SIMPLE SUMMARY: Diagnostic PD-L1 assessment of urothelial cancer to predict a patient’s immune therapy response remains a matter of controversy. Several contributing factors have been discussed; however, systematic studies are lacking. The present study demonstrates that clinically applied PD-L1 sco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weyerer, Veronika, Strissel, Pamela L., Strick, Reiner, Sikic, Danijel, Geppert, Carol I., Bertz, Simone, Lange, Fabienne, Taubert, Helge, Wach, Sven, Breyer, Johannes, Bolenz, Christian, Erben, Philipp, Schmitz-Draeger, Bernd J., Wullich, Bernd, Hartmann, Arndt, Eckstein, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150350/ https://www.ncbi.nlm.nih.gov/pubmed/34066058 http://dx.doi.org/10.3390/cancers13102327

Ejemplares similares

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
por: Kubon, Jennifer, et al.
Publicado: (2020)

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
por: Eckstein, Markus, et al.
Publicado: (2020)

Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort
por: Weyerer, Veronika, et al.
Publicado: (2021)

High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy
por: Taubert, Helge, et al.
Publicado: (2021)

TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers
por: Weyerer, Veronika, et al.
Publicado: (2021)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node Stage
por: Eckstein, Markus, et al.
Publicado: (2020)

Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients
por: Eckstein, Markus, et al.
Publicado: (2021)

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
por: Eckstein, Markus, et al.
Publicado: (2018)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients
por: Eckstein, Markus, et al.
Publicado: (2018)

Endogenous Retroviral–K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma
por: Weyerer, Veronika, et al.
Publicado: (2021)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
por: Sikic, Danijel, et al.
Publicado: (2020)

Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
por: Kahlmeyer, Andreas, et al.
Publicado: (2019)

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2017)

Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort
por: Kullmann, Friederike, et al.
Publicado: (2023)

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis
por: Sikic, Danijel, et al.
Publicado: (2017)

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts
por: Sikic, Danijel, et al.
Publicado: (2019)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
por: Bellut, Julia, et al.
Publicado: (2017)

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants
por: Eckstein, Markus, et al.
Publicado: (2018)

Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients
por: Abdulrahman, Amer, et al.
Publicado: (2019)

Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients
por: König, Paul, et al.
Publicado: (2020)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors
por: Marquardt, Alexander, et al.
Publicado: (2022)

The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors
por: Jasinski-Bergner, Simon, et al.
Publicado: (2022)

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
por: Worst, Thomas S., et al.
Publicado: (2018)

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions
por: Keck, Bastian, et al.
Publicado: (2021)

HLA-E expression and its clinical relevance in human renal cell carcinoma
por: Seliger, Barbara, et al.
Publicado: (2016)

Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients
por: Stöhr, Christine G., et al.
Publicado: (2019)

Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
por: Morsch, Ronja, et al.
Publicado: (2020)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes
por: Rinaldetti, Sebastien, et al.
Publicado: (2017)

Risk Factor Analysis for Long-Term Graft Survival Following Pediatric Kidney Transplantation: The Importance of Pretransplantation Time on Dialysis and Donor/Recipient Age Difference
por: Marcou, Marios, et al.
Publicado: (2023)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lt7jedacspm1eptl2jniej52cc